# What can we do to enhance cognitive care in Parkinson's disease?

**Authors:** Dana Pourzinal, Deborah Brooks, John D. O'Sullivan, Sharon L. Naismith, Nadeeka N. Dissanayaka

PMC · DOI: 10.1002/dad2.70276 · Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring · 2026-02-22

## TL;DR

This paper discusses the overlooked issue of cognitive care in Parkinson's disease and highlights the need for updated guidelines and standardized practices.

## Contribution

The paper identifies gaps in current cognitive care practices for Parkinson's disease and emphasizes the need for updated guidelines and standardized recommendations.

## Key findings

- Cognitive impairment in Parkinson's disease is often overlooked due to limited clinical evaluation opportunities.
- Outdated guidelines and inconsistent care pathways contribute to poor cognitive care for Parkinson's patients.
- A shift is occurring towards a stronger emphasis on cognitive care in Parkinson's disease.

## Abstract

For people living with Parkinson's disease (PD), cognitive impairment is a salient concern. The cumulative risk of mild cognitive impairment and dementia increases as the disease progresses, which contributes to loss of functional independence and increased institutionalization at late stages of PD. Yet, due to scarcity of time and resources, cognition is often an overlooked topic in busy neurology clinics. There are few opportunities for cognitive evaluation during clinical consults, and where it does occur, assessment methods are varied and unstandardized. Diagnostic and post‐diagnostic care pathways for cognitive decline vary across clinical services, leaving people with PD falling through the resonant cracks of our healthcare systems. This perspective article highlights current gaps and inconsistencies in the diagnosis, evaluation, and management of cognitive disorders in PD. In doing so, we explore ways in which some of these issues may be rectified through best practice guidelines and critically analyze those that are more difficult to address.

Guidelines for cognitive disorders in PD are outdated.A literature search revealed key issues impacting diagnostic certainty and quality of care.There is a critical need for updated guidelines and standardized recommendations.A shift is occurring in persistent nihilistic attitudes and stronger emphasis on cognitive care.

Guidelines for cognitive disorders in PD are outdated.

A literature search revealed key issues impacting diagnostic certainty and quality of care.

There is a critical need for updated guidelines and standardized recommendations.

A shift is occurring in persistent nihilistic attitudes and stronger emphasis on cognitive care.

## Linked entities

- **Diseases:** Parkinson's disease (MONDO:0005180)

## Full-text entities

- **Genes:** SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, ACHE (acetylcholinesterase (Yt blood group)) [NCBI Gene 43] {aka ACEE, ARACHE, N-ACHE, YT}
- **Diseases:** cognitive symptoms (MESH:D019954), functional (MESH:D003291), neuronal alpha-synucleinopathies (MESH:D000080874), DLB (MESH:D020961), AD (MESH:D000544), impairment in (MESH:D060825), mental disorder (MESH:D001523), sleep disturbance (MESH:D012893), PD (MESH:D010300), Movement Disorder (MESH:D009069), Cognitive decline (MESH:D003072), motor impairment (MESH:D000068079), Parkinson (MESH:D010302), Dementia (MESH:D003704), MDS (MESH:C000719191), mental ill health (OMIM:603663), neurocognitive disorder (MESH:D019965)
- **Chemicals:** memantine (MESH:D008559), atomoxetine (MESH:D000069445), rasagiline (MESH:C031967), AbbVie (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12928000/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12928000/full.md

---
Source: https://tomesphere.com/paper/PMC12928000